tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alnylam price target raised to $450 from $342 at Scotiabank

Scotiabank raised the firm’s price target on Alnylam (ALNY) to $450 from $342 and keeps an Outperform rating on the shares. The company’s beat and raise underscores the “stellar” early launch momentum of Amvuttra in transthyretin amyloid cardiomyopathy, the analyst tells investors. The firm is increasing its price target to reflect updated expectations for Amvuttra’s growth trajectory.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1